Myeloid-Derived Suppressor Cells

Myeloid cells developed evolutionarily as a major mechanism to protect the host. They evolved as a critical barrier against infections and are important contributors to tissue remodeling. However, in cancer, myeloid cells are largely converted to serve a new master-tumor cells. This process is epito...

Full description

Saved in:
Bibliographic Details
Published inCancer immunology research Vol. 5; no. 1; p. 3
Main Author Gabrilovich, Dmitry I
Format Journal Article
LanguageEnglish
Published United States 01.01.2017
Subjects
Animals
Biomarkers
Cell Differentiation
Humans
Immunomodulation
Molecular Targeted Therapy
Myeloid-Derived Suppressor Cells - cytology
Myeloid-Derived Suppressor Cells - drug effects
Myeloid-Derived Suppressor Cells - immunology
Myeloid-Derived Suppressor Cells - metabolism
Neoplasms - genetics
Neoplasms - immunology
Neoplasms - metabolism
Neoplasms - pathology
Organ Specificity - immunology
Phenotype
Signal Transduction
Online AccessGet more information

Cover

More Information
Summary:Myeloid cells developed evolutionarily as a major mechanism to protect the host. They evolved as a critical barrier against infections and are important contributors to tissue remodeling. However, in cancer, myeloid cells are largely converted to serve a new master-tumor cells. This process is epitomized by myeloid-derived suppressor cells (MDSC). These cells are closely related to neutrophils and monocytes. MDSCs are not present in the steady state of healthy individuals and appear in cancer and in pathologic conditions associated with chronic inflammation or stress. These cells have emerged as an important contributor to tumor progression. Ample evidence supports a key role for MDSCs in immune suppression in cancer, as well as their prominent role in tumor angiogenesis, drug resistance, and promotion of tumor metastases. MDSCs have a fascinating biology and are implicated in limiting the effects of cancer immunotherapy. Therefore, targeting these cells may represent an attractive therapeutic opportunity. Cancer Immunol Res; 5(1); 3-8. ©2016 AACR.
ISSN:2326-6074
DOI:10.1158/2326-6066.CIR-16-0297